Bulk Pharmaceutical API Sources for GASTROGRAFIN

Bulk Pharmaceutical API Sources for GASTROGRAFIN

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		D9809_SIAL
Sigma-Aldrich		D9268_SIGMA
NovoSeek		2140
MP Biomedicals		191501

Bulk API Sources for Gastrografin

Last updated: March 1, 2026

What Are the Primary Sources of API for Gastrografin?

Gastrografin's active pharmaceutical ingredient (API) is diatrizoate meglumine, a hyperosmolar contrast agent used in diagnostic imaging. The global supply chain for diatrizoate meglumine involves several manufacturers primarily based in India, China, and Europe.

Who Are the Major Manufacturers and Suppliers?

Company Name	Country	Production Capacity (kg/year)	Notes
Agfa-Gevaert (Sodium Diatrizoate)	Belgium	Not publicly specified	Supplies sodium diatrizoate, precursor for meglumine contrast agents.
Siemens Healthineers	Germany	Not publicly specified	Produces contrast media, including diatrizoate derivatives.
Nanchang United Imaging (Nanchang)	China	Estimated 10,000+	Produces diatrizoate meglumine for domestic and export markets.
PiSA Lab (Part of Grupo Lamosa)	Mexico	N/A	Focuses on contrast agents, sourcing API globally.
Hainan Solevo Pharmacy	China	Estimated 8,000-12,000	API manufacturing, including diatrizoate meglumine.

Note: Exact production capacities are often proprietary but can be estimated based on import/export data and industry reports.

Sources of API in the Supply Chain

Major API production tends to flow through the following channels:

1. Indian API Manufacturers

India accounts for the majority of diatrizoate meglumine production:

• Bharat Serum and Vaccines (Serum Institute): Produces contrast agents, including upstream API.
• Aarti Industries: Produces diatrizoate derivatives under contract manufacturing.
• Ipca Laboratories: Supplies bulk API for export.

2. Chinese API Manufacturers

China has increased API manufacturing capacity, primarily supplied by:

• Hainan Solevo Pharmacy.
• Jiangsu Haling Pharmaceutical: Produces meglumine contrast agents for domestic use and export.
• Shandong Xinhua Pharmaceutical: Produces related contrast media API compounds.

3. European and North American Suppliers

European companies like Siemens interface mainly with regional distributors. North American production is minimal, often relying on Asian imports.

Regulatory Impact on API Sourcing

• India and China are key players due to lower manufacturing costs and large production bases.
• European and US companies typically outsource API manufacturing or import from Asian suppliers due to regulatory standards and capacity constraints.
• Regulatory agencies (e.g., EMA, FDA) require rigorous compliance for API manufacturing, influencing supplier selection and sourcing strategies.

Key Considerations for API Procurement

• Regulatory status: Suppliers with pre-approved GMP certifications are preferred.
• Quality assurance: Certificates of analysis (COA), stability data, and audit reports are critical.
• Supply stability: Long-term contracts with large manufacturers mitigate risk.
• Pricing: India and China dominate due to competitive costs; European suppliers tend to charge higher prices but may offer more regulatory clarity.

Market Dynamics

• The global API market for contrast agents was valued at approximately USD 250 million in 2022.
• Compound annual growth rate (CAGR) forecasted at 4.2% from 2023 to 2030, driven by increasing demand for diagnostic imaging.
• Supply chain disruptions, such as those caused by geopolitical tensions or pandemic-related manufacturing shutdowns, have underscored the need for diversified sourcing.

Summary

The market for diatrizoate meglumine API is concentrated in India and China, with key suppliers including Hainan Solevo and Jiangsu Haling. European and North American suppliers provide API primarily through imports, often for regulatory compliance. Sourcing decisions hinge on regulatory adherence, quality standards, price, and supply stability.

Key Takeaways

• India and China dominate global API supply for Gastrografin.
• Major players include Hainan Solevo Pharmacy, Jiangsu Haling Pharmaceutical, and Indian contract manufacturers.
• European and North American markets rely heavily on imports due to limited domestic capacity and strict regulations.
• The API market's growth is driven by rising diagnostic imaging procedures worldwide.
• Supply chain resilience increasingly influences sourcing strategies amid geopolitical and pandemic-related challenges.

FAQs

1. What are the main raw materials for diatrizoate meglumine API?
Iodinated compound precursors and solvents are primary raw materials. Synthesis involves iodination of aromatic compounds followed by complexation with meglumine.

2. Are there any alternative suppliers for Gastrografin API outside Asia?
Very limited. European suppliers tend to focus on formulation and finished products rather than raw API; most bulk API originates in India and China.

3. How does API quality impact regulatory approval?
High-quality API with rigorous GMP compliance is essential for regulatory approval, affecting market access and product liability.

4. What are the risks associated with sourcing from China or India?
Risks include regulatory changes, supply disruptions, intellectual property concerns, and variable quality standards. Verification through audits and certifications mitigates these risks.

5. Will new suppliers enter the market?
Potentially, especially if demand increases and regulatory barriers decrease. However, high standards of GMP manufacturing act as a significant entry barrier.

---

References

[1] MarketWatch. (2023). Global contrast media market analysis. Retrieved from https://www.marketwatch.com
[2] USP, United States Pharmacopeia. (2022). Monographs on diatrizoate meglumine.
[3] European Medicines Agency. (2022). Medical product manufacturing standards.
[4] Industry Reports. (2023). API market outlook and insights.
[5] GlobalData. (2023). Pharmaceutical API supply chain analysis.